FI894255A0 - Behandling av typ 2 diabetes mellitus. - Google Patents

Behandling av typ 2 diabetes mellitus.

Info

Publication number
FI894255A0
FI894255A0 FI894255A FI894255A FI894255A0 FI 894255 A0 FI894255 A0 FI 894255A0 FI 894255 A FI894255 A FI 894255A FI 894255 A FI894255 A FI 894255A FI 894255 A0 FI894255 A0 FI 894255A0
Authority
FI
Finland
Prior art keywords
amylin
peptides
type
methods
diabetes
Prior art date
Application number
FI894255A
Other languages
English (en)
Inventor
Garth James Smith Cooper
Howard E Greene
Original Assignee
Amylin Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Corp filed Critical Amylin Corp
Publication of FI894255A0 publication Critical patent/FI894255A0/fi
Priority to FI950530A priority Critical patent/FI950530A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L2924/00—Indexing scheme for arrangements or methods for connecting or disconnecting semiconductor or solid-state bodies as covered by H01L24/00
    • H01L2924/01—Chemical elements
    • H01L2924/01023—Vanadium [V]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Obesity (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FI894255A 1988-01-11 1989-09-08 Behandling av typ 2 diabetes mellitus. FI894255A0 (fi)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FI950530A FI950530A (fi) 1988-01-11 1995-02-07 Menetelmä amyliiniantagonistien valmistamiseksi

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14244788A 1988-01-11 1988-01-11
PCT/US1989/000049 WO1989006135A1 (en) 1988-01-11 1989-01-11 Treatment of type 2 diabetes mellitus

Publications (1)

Publication Number Publication Date
FI894255A0 true FI894255A0 (fi) 1989-09-08

Family

ID=22499881

Family Applications (1)

Application Number Title Priority Date Filing Date
FI894255A FI894255A0 (fi) 1988-01-11 1989-09-08 Behandling av typ 2 diabetes mellitus.

Country Status (9)

Country Link
EP (1) EP0348490B1 (fi)
JP (1) JPH10267914A (fi)
AT (1) ATE128359T1 (fi)
AU (1) AU631112B2 (fi)
DE (1) DE68924372T2 (fi)
DK (1) DK443889A (fi)
FI (1) FI894255A0 (fi)
HK (1) HK1002990A1 (fi)
WO (1) WO1989006135A1 (fi)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE71195B1 (en) * 1989-07-10 1997-02-12 Amylin Corp Use of an amylin antagonist for the manufacture of a medicament for the treatment of obesity and essential hypertension and related disorders
AU8083591A (en) * 1990-06-08 1991-12-31 Symbicom Aktiebolag Therapy and prophylaxis of autoimmune diseases
US5260275A (en) * 1990-08-14 1993-11-09 Amylin Pharmaceuticals, Inc. Hypoglycemics
US5264372A (en) * 1991-03-15 1993-11-23 Amylin Pharmaceuticals, Inc. Receptor-based screening methods for amylin agonists and antagonists
US5321008A (en) * 1991-01-10 1994-06-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions
AU1462692A (en) * 1991-02-25 1992-09-15 Board Of Regents Of The University Of Washington, The Methods for detecting galanin antagonists
US5756460A (en) * 1991-03-06 1998-05-26 Garvan Institute Of Medical Research Human galanin, CDNA clones encoding human galanin and a method of producing human galanin
HU222249B1 (hu) 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
EP0503827A1 (en) * 1991-03-15 1992-09-16 Pfizer Inc. Amylin and calcitonin gene-related peptide use and antagonists thereof
GB9113038D0 (en) * 1991-06-17 1991-08-07 Smithkline Beecham Plc Novel treatment and compositions
GB9113011D0 (en) * 1991-06-17 1991-08-07 Smithkline Beecham Plc Novel treatment and compositions
US5580953A (en) * 1991-08-14 1996-12-03 Amylin Pharmaceuticals, Inc. Amylin antagonist peptides and uses therefor
US6011068A (en) * 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6031003A (en) * 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6001884A (en) * 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5763569A (en) * 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
US5858684A (en) * 1991-08-23 1999-01-12 The Brigham And Women's Hospital, Inc. Method of screening calcium receptor-active molecules
US5688938A (en) * 1991-08-23 1997-11-18 The Brigham & Women's Hospital, Inc. Calcium receptor-active molecules
EP0567626B1 (en) * 1991-11-19 2001-09-19 Amylin Pharmaceuticals, Inc. Amylin agonist peptides and uses therefor
BR9305525A (pt) * 1992-05-15 1995-03-01 Amylin Pharmaceuticals Inc Teste de anticorpos para amilina
DE69321473T2 (de) * 1992-08-06 1999-03-04 Pfizer Inc., New York, N.Y. Amylin muteine
AU6249594A (en) * 1993-02-12 1994-08-29 Amylin Pharmaceuticals, Inc. Mcf-7 binding site assays
US5962314A (en) * 1993-02-23 1999-10-05 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
DK1203761T3 (da) 1994-12-08 2005-04-11 Nps Pharma Inc Calciumreceptoraktive forbindelser
JP4117506B2 (ja) 1996-05-01 2008-07-16 エヌピーエス ファーマシューティカルズ インコーポレイテッド 無機イオン活性化合物
WO2000078805A1 (en) * 1999-06-18 2000-12-28 Protemix Corporation Limited Peptide having preptin functionality
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
CA2755068C (en) 2009-03-12 2018-11-06 Nordic Bioscience A/S Treatment of diabetes and metabolic syndrome
KR20120011667A (ko) * 2010-07-29 2012-02-08 광주과학기술원 당뇨병 치료제의 스크리닝 방법
KR101271218B1 (ko) * 2012-12-07 2013-06-07 광주과학기술원 당뇨병 치료제의 스크리닝 방법
US20150017166A1 (en) * 2013-07-03 2015-01-15 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
WO2015004632A1 (en) 2013-07-12 2015-01-15 Neotope Biosciences Limited Antibodies that recognize iapp
US9951131B2 (en) 2013-07-12 2018-04-24 Prothena Biosciences Limited Antibodies that recognize IAPP
WO2015083125A2 (en) * 2013-12-06 2015-06-11 Prothena Biosciences Limited Antibodies that recognize iapp
JP6643993B2 (ja) * 2013-12-16 2020-02-12 フレゼニウス メディカル ケア ドイッチェランド ゲゼルシャフト ミット ベシュレンクテル ハフツング 膵島様細胞構造体及びそれを調製する方法
EP3142699A4 (en) * 2014-05-16 2017-11-22 Salk Institute for Biological Studies Compositions and methods for treating metabolic disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2052583T3 (es) * 1986-12-04 1994-07-16 Asahi Chemical Ind Derivados de peptidos relacionados con el gel calcitonina.
GB8709871D0 (en) * 1987-04-27 1987-06-03 Turner R C Peptides

Also Published As

Publication number Publication date
ATE128359T1 (de) 1995-10-15
HK1002990A1 (en) 1998-09-30
WO1989006135A1 (en) 1989-07-13
DE68924372T2 (de) 1996-05-09
AU2949489A (en) 1989-08-01
DK443889A (da) 1989-10-27
EP0348490A1 (en) 1990-01-03
DK443889D0 (da) 1989-09-08
AU631112B2 (en) 1992-11-19
EP0348490B1 (en) 1995-09-27
EP0348490A4 (en) 1992-08-12
JPH10267914A (ja) 1998-10-09
DE68924372D1 (de) 1995-11-02

Similar Documents

Publication Publication Date Title
FI894255A0 (fi) Behandling av typ 2 diabetes mellitus.
VALE et al. Somatostatin
Rudolf et al. The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagonist: BIBP3226
REUBI et al. Specific high affinity binding sites for somatostatin-28 on pancreatic 6-cells: Differences with brain somatostatin receptors
Valverde et al. Heterogeneity of plasma glucagon immunoreactivity in normal, depancreatized, and alloxan-diabetic dogs
Pittner et al. Molecular physiology of amylin
Abounader et al. Characterization of neuropeptide Y (NPY) receptors in human cerebral arteries with selective agonists and the new Y1 antagonist BIBP 3226
Chang et al. Radioimmunoassay of secretin: A critical review and current status
Wang et al. Evidence of a paracrine role of neuropeptide-Y in the regulation of insulin release from pancreatic islets of normal and dexamethasone-treated rats
Morgan et al. Purification and characterization of the receptor for insulin-like growth factor I
Chejfec et al. Synaptophysin: a new marker for pancreatic neuroendocrine tumors
Mikkelsen et al. Substance P in the median eminence and pituitary of the rat: demonstration of immunoreactive fibers and specific binding sites
IL122211A0 (en) Modified/chimeric superantigens and their use
Sonntag et al. Increased secretion of somatostatin-28 from hypothalamic neurons of aged rats in vitro
Goltzman et al. Metabolism and biological activity of parathyroid hormone in renal cortical membranes.
Haro et al. Glycosylated human prolactin: alterations in glycosylation pattern modify affinity for lactogen receptor and values in prolactin radioimmunoassay
Koida et al. Abundance and location of 125-I-salmon calcitonin binding site in rat brain
Bordi et al. Immunofluorescence, histochemical and ultrastructural studies for the detection of multiple endocrine polypeptide tumours of the pancreas
Gray et al. Proinsulin in human serum: problems in measurement and interpretation
Matsumura et al. Effects of solution of low pH and taurocholate on release of β-endorphin-like immunoreactivity from human duodenal mucosa in vitro
Otsuki et al. Amylase secretion by isolated pancreatic acini after acute cholecystokinin treatment in vivo
Inoue et al. Amylin release from perfused rat pancreas in response to glucose and arginine
Poitras et al. Motilin synthetic analogues and motilin receptor antagonists
Silver et al. Studies of Serum Protein Abnormalities in Kala Azar.
El-Salhy et al. Neuropeptide contents in the duodenum of non-obese diabetic mice

Legal Events

Date Code Title Description
FD Application lapsed
FD Application lapsed

Owner name: AMYLIN CORPORATION